De-ESCALaTE HPV
Determination of Epidermal growth factor receptor inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus positive oropharyngeal squamous cell carcinoma
Portfolio Study ID: 11723
_____________________________________________________________________________________________________________________
De-ESCALaTE is a pragmatic, randomised, international, multi-centre, open label, Phase III clinical trial determining the optimum treatment for patients with HPV+ OPSCC.
Sponsored by the University of Warwick. Funded by Cancer Research UK.
GENERAL ENQUIRES:
Please email the De-ESCALaTE Team at deescalate@warwick.ac.uk
-------------------------------------
The trial is closed to new sites and now closed to recruitment.
The main results of the study were published in 2018: Main Trial Results Summary
Trial Administrator
Matthew Dalby
Tel: +44 (0)2476572721
Email: m.l.dalby@warwick.ac.uk
Data Entry Clerk
Liz Weaver
Tel: +44 (0)2476573142
Email:
